Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.
Farhad Ravandi-Kashani, MD, of The University of Texas MD Anderson Cancer Center, discusses updates from a phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule. It showed early evidence of an acceptable safety profile, drug tolerability, and antileukemic activity, supporting further dose escalation in patients with acute myeloid leukemia (Abstract 7508).
Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).
Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell transplant is not intended (Abstract LBA3).
Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of patients had a favorable pathologic response (Abstract 5503).
